KCM
PBYI icon

Kennedy Capital Management’s Puma Biotechnology PBYI Stock Holding History

Kennedy Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.08M Sell
873,253
-16,348
-2% -$120K 0.13% 265
2026
Q1 		$5.68M Buy
889,601
+21,286
+2% +$137K 0.12% 264
2025
Q4 		$5.17M Buy
868,315
+685
+0.1% +$3.64K 0.11% 288
2025
Q3 		$4.61M Sell
867,630
-119,371
-12% -$506K 0.1% 310
2025
Q2 		$3.39M Buy
987,001
+75,878
+8% +$242K 0.08% 354
2025
Q1 		$2.7M Buy
911,123
+101,748
+13% +$318K 0.06% 389
2024
Q4 		$2.47M Buy
809,375
+216,329
+36% +$629K 0.05% 482
2024
Q3 		$1.51M Buy
+593,046
New +$1.8M 0.03% 549
2019
Q4 		– Sell
-538,752
Closed -$5.8M – 713
2019
Q3 		$5.8M Buy
+538,752
New +$5.82M 0.14% 268
2015
Q1 		– Sell
-2,844
Closed -$538K – 748
2014
Q4 		$538K Buy
2,844
+1,934
+213% +$429K 0.01% 704
2014
Q3 		$217K Buy
+910
New +$187K ﹤0.01% 756

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's PBYI Position: Q2 2026 in Review

Kennedy Capital Management reduced its Puma Biotechnology (PBYI) stake by 1.8% in Q2 2026, selling an estimated $120K and leaving 873,253 shares worth $7.08M. The position accounts for 0.13% of the portfolio, ranked #265.

Kennedy Capital Management first reported a position in PBYI in Q3 2014 and has held it in 11 quarters since. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Kennedy Capital Management held 873,253 shares of Puma Biotechnology worth $7.08M as of Q2 2026.
  • Kennedy Capital Management sold 16,348 Puma Biotechnology shares in Q2 2026, an estimated $120K.
  • Puma Biotechnology made up 0.13% of Kennedy Capital Management's portfolio in Q2 2026, its #265 holding.
  • Kennedy Capital Management first reported a position in Puma Biotechnology in Q3 2014 and has held it in 11 quarters since.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.